Holen Sie sich die Stockscreener-App
2.13
2.40%
0.05
Handel nachbörslich:
2.11
-0.02
-0.94%
Schlusskurs vom Vortag:
$2.08
Offen:
$2.21
24-Stunden-Volumen:
5.79M
Relative Volume:
13.23
Marktkapitalisierung:
$175.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.64M
KGV:
-5.0402
EPS:
-0.4226
Netto-Cashflow:
$-13.98M
1W Leistung:
-40.17%
1M Leistung:
-45.66%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.98
$2.21
1-Wochen-Bereich:
$1.98
$3.75
52-Wochen-Spanne:
$1.98
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Firmenname
Nervgen Pharma Corp
Sektor
Branche
Telefon
-
Adresse
-
Compare NGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
2.13 | 170.96M | 0 | -31.64M | -13.98M | -0.4226 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nervgen Pharma Corp Stock (NGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | H.C. Wainwright | Buy |
Nervgen Pharma Corp Aktie (NGEN) Neueste Nachrichten
Why Is NervGen Pharma Stock Gaining Tuesday? - Benzinga
NervGen Pharma (NGEN) Reports Promising Gait Analysis Results - GuruFocus
NervGen Pharma Corp. Announces Positive Independent Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery With NVG-291 In Phase 1b/2a CONNECT SCI Study - marketscreener.com
NervGen reports positive gait analysis data for NVG-291 trial - Investing.com
NervGen reports positive gait analysis data for NVG-291 trial By Investing.com - Investing.com Canada
NervGen Pharma Reports Positive Biomechanical Gait Analysis Results for NVG-291 Demonstrating Genuine Neural Recovery in Chronic Tetraplegia - Quiver Quantitative
Spinal cord injury trial: NervGen drug improves walking control - Stock Titan
Assessing NervGen Pharma (NasdaqCM:NGEN) Valuation After Its $60 Million Follow On Equity Offering - Sahm
NervGen Pharma Raises Capital to Advance Therapy for Spinal Cord Injury - techcouver.com
NervGen launches underwritten public offering of shares and warrants - MSN
NGEN Slides As NervGen Pharma Dilution Hits Share Price - timothysykes.com
NervGen Pharma prices 24M share public offering; warrants exercisable at $3.68 - MSN
NervGen Pharma Prices $60 Million Share Offering - Moomoo
HC Wainwright & Co. initiates coverage of NervGen Pharma (NGEN) with buy recommendation - MSN
NervGen Pharma Shares Continue Sliding on Size of $60 Million Share Sale - Moomoo
Keep an eye on the top gainers and losers in Friday's session. - ChartMill
Biggest stock movers Friday: Quantum computing stocks, WDAY, ZM, and more - Seeking Alpha
NervGen Pharma stock tumbles on dilutive share offering By Investing.com - Investing.com India
NervGen Pharma, Medline, sociétés minières d'argent - TradingView
NervGen Pharma stock tumbles on dilutive share offering - Investing.com
NGEN: Joint Book Runners for Recent Offering Announced - GuruFocus
NervGen Pharma (NGEN) Launches $60 Million Public Offering of Sh - GuruFocus
NervGen prices $60M public offering to fund spinal cord injury drug development - Pluang
NervGen prices $60M public offering at $2.50 per share By Investing.com - Investing.com South Africa
NervGen prices $60M public offering at $2.50 per share - Investing.com
NervGen Pharma Corp. Announces Pricing for $60 Million Underwritten Public Offering of Common Shares and Warrants - Quiver Quantitative
Nervgen says co. announces pricing of US$60.0 million public offering of securities - marketscreener.com
Press Release: NervGen Announces Pricing of US$60.0 Million Public Offering of Securities - Moomoo
NGEN: Joint Bookrunners Selected for Upcoming Offering - GuruFocus
NervGen commences underwritten public offering - Investing.com UK
NervGen Pharma (NGEN) Announces Secondary Offering Price Range - GuruFocus
NervGen Pharma (NGEN) Launches Public Offering of Shares and War - GuruFocus
NervGen commences underwritten public offering By Investing.com - Investing.com Australia
NervGen Announces Proposed Public Offering of Securities - marketscreener.com
NervGen Stock Climbs with Trial Approaching, Cash Burn Still a Focus - Bez Kabli
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates - Sahm
NGEN Stock Price, Quote & Chart | NERVGEN PHARMA CORP (NASDAQ:NGEN) - ChartMill
NervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows - TipRanks
NervGen reports Q1 financials, aligns with FDA on Phase 3 - grafa.com
NGEN: NervGen Prepares for RESTORE Study in Chronic Tetraplegia - GuruFocus
NervGen Pharma Announces FDA Meeting Success, Advancements in NVG-291 Study, and Nasdaq Listing Update - Quiver Quantitative
Press Release: NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates - Moomoo
NervGen Pharma (NGEN) 10K Form and Latest SEC Filings 2026 - MarketBeat
NervGen Pharma Narrows Quarterly Loss but Cash Reserves Decline in Q1 2026 Filing - TipRanks
NervGen Pharma (NASDAQ: NGEN) Q1 2026 loss shrinks as cash funds ops to Q2 - Stock Titan
Finanzdaten der Nervgen Pharma Corp-Aktie (NGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):